Evommune (EVMN)
Develops chronic-inflammation therapies centered on EVO756 and EVO301 clinical programs.
$9.70
After-hours close+0.11 (+1.15%)
At close$9.59(+1.48%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.06% | 39.0K shares | |
|---|---|---|---|
| 1 holder · as of Jun 30, 2026 | |||
| Other | 99.94% | 64.88M shares | |
| remainder | |||
64.92M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (64.92M in the company's Sep 23, 2026 report, 36.29M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Eqt Fund Management S.A R.L. | 5.29M | 8.15% | +358.7K | Aug 13, 2026 |
| Ra Capital Management, L.P. | 3.49M | 5.38% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.94M | 2.99% | +821.9K | Aug 14, 2026 |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.93M | 2.97% | 0 | Aug 13, 2026 |
| JPMorgan Chase & Co | 1.55M | 2.39% | +93.7K | Aug 12, 2026 |
| RTW Investments, LP | 1.50M | 2.31% | 0 | Aug 14, 2026 |
| Nan Fung Group Holdings Ltd | 1.44M | 2.22% | 0 | Aug 13, 2026 |
| Point72 Asset Management, L.P. | 1.44M | 2.21% | +1.40M | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.